Chromatin-spliceosome interface protein

Chromatin-spliceosome interface proteins are not a specific molecular entity but denote any of several protein factors that mediate the functional and physical coupling between the state of chromatin (the structure and modifications of DNA and its associated proteins) and the activity of the spliceosome (the multi-component molecular machine responsible for mRNA splicing)[1][2][5]. These proteins include, but are not limited to, RNA helicases (such as DHX15, DHX35), G-patch proteins (such as GPATCH1), SR-related proteins (such as SRRM2), CWC22, and others frequently involved in both splicing and interactions with chromatin-associated marks or structures[1][3]. The combined action of these proteins is essential for regulated gene expression, quality control of splicing reactions, and integration of chromatin cues into mRNA processing. Dysregulation of these interface functions has been linked to diseases including cancer and neurodegenerative disorders[2][5]. The current term represents a multi-protein interface rather than a single defined therapeutic target, and specific drug interactions, established biomarkers, or safety concerns are not known for "Chromatin-spliceosome interface proteins" as a group. For structured target curation, it is preferable to refer to specific proteins or complexes (e.g., "GPATCH1," "DHX35," "PRP8") rather than the collective interface. Note on nomenclature: This is not a singular, canonically named molecule or receptor but a functional concept encompassing multiple proteins and interactions. Therefore, it is "incorrect" under the conventions requested for unambiguous molecular targets[1][2][5].

Modulation of spliceosome assembly or disassembly Regulation of splicing fidelity via chromatin context